APM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer...

Stats
今日成交量	7 685.00
平均成交量	2.49M
市值	23.28M
EPS	$0 ( 2024-04-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.32
ATR14	$0.0650 (1.16%)

Aptorum Group Ltd 相关性

10 最正相关
MSTR	0.943
CYTO	0.935
TNGX	0.934
NAKD	0.934
AHPI	0.93
TRIT	0.929
SIRI	0.928
IMV	0.924
TENX	0.923
JAGX	0.923

10 最负相关
PUCK	-0.948
THCPU	-0.947
OVLY	-0.945
BRACU	-0.942
XM	-0.939
INOD	-0.935
NCAC	-0.935
TGTX	-0.934
MCAA	-0.933
TETC	-0.932

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Aptorum Group Ltd 财务报表

Annual	2022
营收:	$1.30M
毛利润:	$80 065.00 (6.18 %)
EPS:	$-14.89

FY	2022
营收:	$1.30M
毛利润:	$80 065.00 (6.18 %)
EPS:	$-14.89

FY	2021
营收:	$1.54M
毛利润:	$81 854.00 (5.31 %)
EPS:	$-7.94

FY	2020
营收:	$911 509
毛利润:	$-103 514 (-11.36 %)
EPS:	$2.24

Financial Reports:

No articles found.

Aptorum Group Ltd

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.